MedPath

Randomized phase II study comparing pegylated interferon alpha-2b combined with intra-arterial 5-fluorouracil and sorafenib alone for advanced hepatocellular carcinoma

Not Applicable
Recruiting
Conditions
advanced hepatocellular carcinoma
Registration Number
JPRN-UMIN000008710
Lead Sponsor
Iwate Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Exclusion criteria for treatment were as follows:1) pregnancy women 2) patients who had allergic disorder and severe disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath